Maxcyte, Inc.

Health Care
Biotechnology: Commercial Physical & Biological Resarch
www.maxcyte.com

Moat Score

Market Cap $376.61M
PE -11
Debt $NaN
Cash $36.96M
EV $NaN
FCF -$21.23M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$35.74M
EBIT	-$46.11M
ROE	-17%
ROA	-19%
FCF	-$21.23M
Equity	$213.30M
Growth Stability	1
PE	-10.54
PB	1.77
P/FCF	-17.74
P/S	8.26
Price/Cash	0.1
Net Margins	-102%
Gross Margins	86%
Op. Margins	-101%
Sales Growth YoY	2%
Sales Growth QoQ	-22%
Sales CAGR	13%
Equity CAGR	79%
Earnings Growth YoY	3%

Earnings Growth QoQ	23%
Sales CAGR 5Y	13%
Equity CAGR 5Y	79%
Earnings CAGR 3Y	7%
Sales CAGR 3Y	7%
Equity CAGR 3Y	-7%
Market Cap	$376.61M
Revenue	$45.60M
Assets	$248.61M
Cash	$36.96M
Shares Outstanding	104.61M
Moat Score	2%
Working Capital	155.29M
Current Ratio	9.81
Gross Profit	$39.21M
Shares Growth 3y	3%
Equity Growth QoQ	-4%
Equity Growth YoY	-9%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.

SEC Filings

Direct access to Maxcyte, Inc. (MXCT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Maxcyte, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Maxcyte, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Maxcyte, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Maxcyte, Inc..

Years

Calculation mode

= -$212M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$21M	-$21M	-$21M	-$21M	-$21M	-$21M	-$21M	-$21M	-$21M	-$21M	-$21M	-$212M
DCF		-$19M	-$18M	-$16M	-$14M	-$13M	-$12M	-$11M	-$9.9M	-$9M	-$8.2M	-$82M
Value	-$212M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-60%	-45%	-56%	-53%	-92%	-102%
ROA	-	-21%	-6%	-10%	-18%	-19%
ROE	-	-36%	-7%	-9%	-16%	-17%

Bad Net Margins (-101.75%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	21%	30%	31%	-7%	13%
Earnings YoY growth	-	-8%	61%	24%	61%	-
Equity YoY growth	-	144%	691%	-3%	-9%	79%
FCF YoY growth	-	8%	34%	129%	-24%	-